Natalie Gukasyan

Assistant Professor

Johns Hopkins University School of Medicine

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Natalie Gukasyan is an Assistant Professor at Johns Hopkins University School of Medicine in the United States. Her research primarily focuses on psychedelic therapies, informed consent in psychedelic-assisted therapy, and the therapeutic potential of psilocybin and ketamine for various mental health conditions. Recent publications include studies on the safety of psilocybin in bipolar disorder and the effects of psychedelics on eating disorders.

Articles (16)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Collaborators (3)

Alan K. Davis

Johns Hopkins University

UNITED STATES

View details

Colleen Schreyer

UNITED STATES

View details

Denis Antoine

Johns Hopkins University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Natalie Gukasyan

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Reframing psychedelic regulation: Tools, not treatments

Ketamine and the Consequences of Positive Psychedelic Exceptionalism

The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder

Informed Consent in Psychedelic-Assisted Therapy.

Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals.

Beyond the numbers: reimagining healing with psychedelics for eating disorders.

Psilocybin in Bipolar II Study Provides Preliminary Data on Safety.

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.

Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

Menstrual Changes and Reversal of Amenorrhea Induced by Classic Psychedelics: A Case Series

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

Psychedelic-Assisted Therapy for People with Eating Disorders

Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy

Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up

Relationship between cannabis use frequency and major depressive disorder in adolescents: Findings from the National Survey on Drug Use and Health 2012–2017

Enhancing patient navigation with contingent financial incentives for substance use abatement in persons with HIV and substance use.

Collaborators (3)

Alan K. Davis

Colleen Schreyer

Denis Antoine

Make your next move.